Abemaciclib mesylate (LY2835219)

For research use only. Not for use in humans.

目录号:S7158 中文名称:甲磺酸阿贝西尼

Abemaciclib mesylate (LY2835219) Chemical Structure

CAS No. 1231930-82-7

Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 4644.52 现货
RMB 2203.44 现货
RMB 3333.88 现货
RMB 6544.35 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Abemaciclib mesylate (LY2835219)发表文献47篇:

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述 Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。
靶点
CDK4 [1]
(Cell-free assay)
CDK6 [1]
(Cell-free assay)
2 nM 10 nM
体外研究

LY2835219是一种口服有效的细胞周期蛋白依赖性激酶(CDK)抑制剂,靶向作用于CDK4(cyclin D1)和CDK6(cyclin D3)细胞周期通路,具有潜在的抗肿瘤活性。LY2835219特异性抑制CDK4和6,从而在早G1期抑制视网膜母细胞瘤(Rb)蛋白磷酸化。抑制Rb磷酸化,防止CDK-介导的G1-S期转换,从而使细胞周期停滞在G1期,抑制DNA合成,且抑制癌细胞生长。某些类型的癌症中丝/苏氨酸激酶CDK4/6的过表达,导致细胞周期调节失控。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human COLO205 cells NVfEOVZkTnWwY4Tpc44h[XO|YYm= NWPzeZlkOjRiaB?= MnnaTY5pcWKrdHnvckBw\iCFRFu0M|YhcW5iaIXtZY4hS0:OT{KwOUBk\WyuczDhd5Nme3OnZDDhd{Bu[XirbYXtJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdzIIDoZZNmKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqew>? M1zxU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG1OVcyLz5{NkGxOVU4OTxxYU6=
human COLO205 cells MnvKSpVv[3Srb36gZZN{[Xl? M4nLUFI1KGh? MVfJcohq[mm2aX;uJI9nKEOGS{SvOkBqdiCqdX3hckBEV0yRMkC1JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiUnKgdIhwe3Cqb4L5cIF1cW:wIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIxie2W{LYPjZY5vcW6pIH\seY9z\XOlZX7j[UBucWO{b4DsZZRmKGO7dH;t[ZRzcWNiYX7hcJl{cXN? NV7FTWpPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVU2PzFpPkK2NVE2PTdzPD;hQi=>
insect cells  NWriNlFDTnWwY4Tpc44h[XO|YYm= NFLoO3g2OCCvaX7z NX;QcVMzUW6qaXLpeIlwdiCxZjDoeY1idiCFRFu0M4N6[2yrbjDENUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHnvckBw\iCFVGLGJIFnfGW{IEWwJI1qdnNiYomgcYlkem:ybHH0[UB{[2mwdHnscIF1cW:wIHPveY51\XJuIFnDOVA:OiCwTR?= NHXGS289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
insect cells  MUjGeY5kfGmxbjDhd5NigQ>? NE\XfVM2OCCvaX7z NUH0NXNJS2:vcHX0bZRqfmViaX7obYJqfGmxbjDv[kBpfW2jbjDDSGs1N2O7Y3zpckBFOSCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KGG|c3Xzd4VlKGG|IIDoc5NxcG:{eXzheIlwdiCxZjDDWHJHKGGodHXyJFUxKG2rboOgZpkhVWmlaHHlcIl{NU2nboTlckBxdG:2IHHuZYx6e2m|IHnuJJBz\XOnbnPlJI9nKEGWUDygT4k:OC54IH7N MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNUW3NUc,OjZzMUW1O|E9N2F-
HCT116 NY\qbHcxSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MYS3NkBpenN? MVzJR|UxKD1iMD61OEDPxE1? NVvKUYxbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxOlU{PDFpPkOwNVY2OzRzPD;hQi=>
MCF7 NHP4W2lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MX:3NkBpenN? NXj6dZFOUUN3MDC9JFAvPzFizszN NIfFNXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEG2OVM1OSd-M{CxOlU{PDF:L3G+
PANC1 MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NUXlR|VqPzJiaILz NEH0SFBKSzVyIE2gOU46PCEQvF2= MmfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNkWzOFEoRjNyMU[1N|QyRC:jPh?=
Sf9 NU[5dlk4TnWwY4Tpc44h[XO|YYm= NFzLTnVKdmirYnn0bY9vKG:oIFPET|EwS3mlbHnuJGIhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{YXygbY5n\WO2ZXSgbY5{\WO2IGPmPUBk\WyuczD1d4lv\yCqaYP0c45mKEhzIHHzJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDb[4FudWFvM{PQYWFVWCxiSVO1NEA:KDBwM{exJO69VS5? M2DCVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{SxPFU{Lz5{Nke0NVg2OzxxYU6=
Sf9 M2W3[2Z2dmO2aX;uJIF{e2G7 Mn3wPVAhdWmwcx?= MYDJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDDSGs1KCh2IITvJFMxOyC{ZYPp[JVmeylxY4njcIlvKERzIDi0JJRwKDJ7NTDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKHOoOTDj[YxteyC3c3nu[{BENXSncn3pcoFtKHKndHnuc4Jt[XO2b33hJIZz[WevZX70JIF{KHO3YoP0doF1\SCjZoTldkA6OCCvaX7zJIJ6KFupYX3tZU0{O1CfQWTQJIJie2WmIH3pZ5Jw[mW2YTDzZ4lvfGmubHH0bY9vKGOxdX70bY4tKEurIE2gNE4xODJizszNMi=> NWX1TlRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO|ExOzZpPkK3NVcyODN4PD;hQi=>
Sf9 MX;GeY5kfGmxbjDhd5NigQ>? MlLLPVAhdWmwcx?= NHPmZoFKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIZ2dGxibHXu[5RpKGi3bXHuJG4ufGW{bXnuZYwhT1OWLYTh[4dm\CCFRFu2JEgyKHSxIEOyOkBz\XOrZIXld{kw[3mlbHnuJGQyKCh2IITvJFI6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{B2e2mwZzDDMZRmem2rbnHsJJJmfGmwb3LsZZN1d22jIH\yZYdu\W62IHHzJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JHto[W2vYT2zN3BeSVSSIHLhd4VlKG2rY4LvZoV1[SC|Y3nueIltdGFuIFvpJF0hOC5yMTFOwG0v NWizfVZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO|ExOzZpPkK3NVcyODN4PD;hQi=>
Sf21 MYrGeY5kfGmxbjDhd5NigQ>? M1L3TmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR{11\XKvaX7hcEBJcXN4LYTh[4dm\CCFRFu3M4N6[2yrbjDIM24ufGW{bXnuZYwhT1OWLYTh[4dm\CCPQWSxJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lIyKGmwc3XjeEBk\WyuczD1d4lv\yClZHu3JJN2[nO2cnH0[UBx\XC2aXTlMEBMcSB;IEOuPVEh|ryPLh?= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
COLO205 NFizfYhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MlrrPVYhcHK| NXfLXHJiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGGodHXyJFk3KGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDBwNE[g{txONg>? NWLjTGFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwO|QzPTRpPkK5NFc1OjV2PD;hQi=>
U87MG NFjGco1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NVvWfnc{PzJiaILz M{C3RmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFTBVGkhe3SjaX7pcoch[mG|ZXSgZZN{[XluIFnDOVAhRSByLkC0PFEh|ryPLh?= MofVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{NEe4OVcoRjJ7MkS3PFU4RC:jPh?=
Sf9 M3vXemZ2dmO2aX;uJIF{e2G7 NWXERpBXUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhS0SNNDCoV|QhfG9iRUOwN{Bz\XOrZIXld{kwS3mlbHnuJGQyKCiTNDD0c{BKOjl3IILld4llfWW|KTDlfJBz\XO|ZXSgbY4he2Z7IHPlcIx{KHW|aX7nJHJjKHC{b4TlbY4hMDd5MzD0c{A6OjhicnXzbYR2\XNrIHHzJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDbN|NRZS2DVGCgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDt[ZRpd2RuIFnDOVAhRSByLkCwNkDPxE1w MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR{OUizNkc,Ojl2Mkm4N|I9N2F-
Sf9 M{HIPGZ2dmO2aX;uJIF{e2G7 NXf1Z5VtQTBibXnudy=> M4\5XWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR2RMPiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDobZN1d26nIFixJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JGFFWC2JbH:gZZN{[XluIFnDOVAhRSByLkCwO|gh|ryPLh?= MlHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
Sf9 MVPGeY5kfGmxbjDhd5NigQ>? NHfiUIRKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBETEt2IDjNNUB1dyCDM{K2JJJme2mmdXXzLU9EgWOuaX6gSFEhMFF2IITvJGkzQTVicnXzbYR2\XNrIHX4dJJme3OnZDDpckB{\jliY3XscJMhfXOrbnegVoIheHKxdHXpckApPzd|IITvJFkzQCC{ZYPp[JVmeyliYYOgd5Vje3S{YYTlJIlvKHC{ZYPlcoNmKG:oIGuzN3BeNUGWUDDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pIH3leIhw\CxiSVO1NEA:KDBwMEGg{txONg>? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR{OUizNkc,Ojl2Mkm4N|I9N2F-
Sf9 MVnGeY5kfGmxbjDhd5NigQ>? MWW5NEBucW6| NEnaTG9KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGNFUzFxQ4njcIlvKER|IHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkmgbY5{\WO2IHPlcIx{KHW|aX7nJIhqe3SxbnWgTFEhe3Wkc4TyZZRmKGGodHXyJFkxKG2rboOgZpkhSUSSLVfsc{Bie3OjeTygTWM2OCB;IECuNFU3KM7:TT6= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR{OUizNkc,Ojl2Mkm4N|I9N2F-
MDA-MB-231 M3XtR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5? M2O5UVczKGi{cx?= Ml3jRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFczKGi{czDifUBFSVCLIIP0ZYlvcW6pIHLhd4VlKGG|c3H5MEBKSzVyIE2gNE4yQTFizszNMi=> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR{OUizNkc,Ojl2Mkm4N|I9N2F-
COLO205 MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFv NUC5OWlJQTZiaILz NGnyXJRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPPUG8zODViY3XscJMh[W[2ZYKgPVYhcHK|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUAxNjJzNzFOwG0v M1\zeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW5Nlc1Lz5{OUS1PVI4PDxxYU6=
MDA-MB-468 M4PTXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5? MkOyPVYhcHK| NHezOVlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi12NkigZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSB2LkiwPEDPxE1w MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3OUK3OEc,Ojl2NUmyO|Q9N2F-
COLO205 MX7Jcohq[mm2aX;uJI9nKEOGS{SgbY4hcHWvYX6= Ml[1NE4yKHSxIEGwJJVO MmW5NlQhcHK| MX\Jcohq[mm2aX;uJI9nKEOGS{SgbY4hcHWvYX6gR29NVzJyNTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hfG:2YXygVoIheHKxdHXpckBt\X[nbDDheEAxNjFidH:gNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?= MoPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUmyO|QoRjJ7NEW5Nlc1RC:jPh?=
COLO205 NGfvVHJE\WyuIHP5Z4xmKGG|c3H5 Ml\KeZAhfG9iMUCgeW0> MVGyOEBpenN? NYTPNXJ4S2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hS0:OT{KwOUBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|IwVSCyaHHz[UB2eCC2bzCxNEB2VSCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDGRWNUKGGwYXz5d4l{ M1HXdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW5Nlc1Lz5{OUS1PVI4PDxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Rb(S780) / Rb / p21; 

PubMed: 26909611     


Effects of LY2835219 on RB phosphorylation and p21 expression were evaluated by immunoblotting at indicated concentrations (A)

p-ERK / ERK / p-Akt / Akt / p-mTOR(S2448) / mTOR; 

PubMed: 26909611     


Effects of LY2835219 on RB phosphorylation and p21 expression were evaluated by immunoblotting at indicated time points (B).

pRb(S795) / E2F1 / Cyclin A2 / Cyclin E2; 

PubMed: 27748766     


(c) MCF-7 and MR cells were treated with 100 nm LY2835219 and collected at indicated times. Immunoblots were performed with the indicated antibodies. (d) MCF-7 and MR cells were treated with increasing concentrations of LY2835219 and harvested after 24 h; lysates were then subjected to immunoblotting.

26909611 27748766
Growth inhibition assay
Cell viability; 

PubMed: 26909611     


Cell viability of OSC-19, FaDu, and YD-10B cells treated with LY2835219 at indicated concentrations. Data are representative of three independent experiments: mean ± SEM.

26909611
体内研究 LY2835219-MsOH处理脑的剂量百分比为0.5–3.9%。LY2835219-MsOH处理皮下和颅内胶质瘤模型(U87MG),抑制肿瘤生长,这种作用存在剂量依赖性,不管是单独处理,还是与Temozolomide联用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 Water 100 mg/mL (165.92 mM)
DMSO 83 mg/mL (137.71 mM)
Ethanol '''24 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water
100mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 602.7
化学式

C27H32F2N8.CH4O3S

CAS号 1231930-82-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04627064 Not yet recruiting Drug: Abemaciclib|Drug: MK-6482 Clear Cell Renal Cell Carcinoma Dana-Farber Cancer Institute|Eli Lilly and Company March 2021 Phase 1
NCT04169074 Not yet recruiting Drug: Abemaciclib|Drug: Abemaciclib plus nivolumab HNSCC University of Arizona January 1 2021 Phase 2
NCT04408924 Not yet recruiting Drug: Abemaciclib Metastatic Castration-Resistant Prostate Cancer Eli Lilly and Company December 18 2020 Phase 2
NCT04238819 Recruiting Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide Relapsed Solid Tumor|Refractory Solid Tumor Eli Lilly and Company November 9 2020 Phase 1
NCT04514159 Recruiting Drug: ZN-c5|Drug: Abemaciclib Breast Cancer Zeno Alpha Inc. November 2020 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is your product S7158 LY2835219 “mesylate salt form”?

  • 回答:

    Our S7158 LY2835219 is mesylate salt form.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

相关CDK产品

Tags: 购买Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)供应商 | 采购Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)价格 | Abemaciclib mesylate (LY2835219)生产 | 订购Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID